|Bid||172.81 x 1100|
|Ask||173.24 x 800|
|Day's Range||170.52 - 174.36|
|52 Week Range||90.14 - 196.00|
|Beta (3Y Monthly)||2.37|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||223.58|
GW Pharmaceuticals PLC (GWPH) closed at $175.80 in the latest trading session, marking a -0.01% move from the prior day.
Zynerba (ZYNE) gets a new U.S. patent covering methods of treating autism spectrum disorder with cannabidiol, a key compound of its lead pipeline candidate, Zygel.
No matter what the FDA decides with regard to cannabidiol as a food or beverage additive, it'll have little bearing on consumers or investors.
The Zacks Analyst Blog Highlights: GW Pharmaceuticals, Canopy Growth, Aurora Cannabis and Hexo
Analysts estimate that nearly 65 million Americans have tried CBD and 63% have found it effective. What's more, CBD is a growing industry with sales expected to rise 55% to $648 million in 2019.
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW, along with its U.S. subsidiary Greenwich Biosciences, has received U.S. FDA approval for EPIDIOLEX (cannabidiol) oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older and which is now available by prescription in the U.S. The Company has submitted a regulatory application in Europe for the adjunctive treatment of seizures associated with LGS and Dravet syndrome.
Should you put your hard-earned money into these stocks? We detail the investment opportunities, the risks, and regulations in the cannabis space.
Several CBD manufacturers, researchers, farmers and retailers have urged the regulatory authority to allow the use of cannabis.
Comparing GW Pharmaceuticals’ Returns to PeersGW PharmaceuticalsGW Pharmaceuticals (GWHP) is primarily into the development of cannabis-derived prescription medicines. Liquid cannabidiol (or CBD) is the leading product in the company’s
Does GW Pharmaceuticals PLC (GWPH) have what it takes to be a top stock pick for momentum investors? Let's find out.